

1: Introduction, *Raffaele De Caterina, David J. Moliterno, and Steen Dalby Kristensen*

### **Section 1: Pathophysiology of thrombosis**

2: Arterial thrombosis: Pathophysiological background, *Lina Badimon and Gemma Vilahur*

3: Venous thrombosis and thromboembolism: Pathophysiological background, *Marcello Di Nisio, Nicola Potere, Harry R. Buller, and Nick van Es*

4: Thrombosis & thromboembolism in atrial fibrillation: Pathophysiological background, *Peter Calvert, Nicola Tidbury, and Gregory Y. H. Lip*

5: Thrombosis on foreign surfaces and devices, *Tobias Geisler*

### **Section 2: Clinical pharmacology of antithrombotic drugs**

6: Aspirin, *Carlo Patrono and Bianca Rocca*

7: Platelet P2Y<sub>12</sub> inhibitors, *Manan Pareek and Deepak L. Bhatt*

8: Dipyridamole, cilostazol, GP IIb/IIIa inhibitors, and PAR-1 antagonists, *Luis Ortega-Paz and Dominick Angiolillo*

9: Heparins, fondaparinux, hirudin, bivalirudin, argatroban and danaparoid, *Renske Olie and Hugo ten Cate*

10: Vitamin K antagonists, *Freek W.A. Verheugt and Marc Brouwer*

11: Dabigatran, *Alex Benz and Stefan Hohnloser*

12: Oral factor Xa (FXa) inhibitors, *Lars C. Wallentin, Agneta Siegbahn, Peter Svensson, and Hakan Wallen*

13: Forthcoming oral factor XIa and FXIIa inhibitors, *James C. Fredenburgh and Jeffrey I. Weitz*

14: Thrombolytic therapy and ancillary antithrombotic therapies, *Peter R Sinnaeve and Frans Van de Werf*

### **Section 3: Therapeutic strategies**

15: Antithrombotic strategies in primary cardiovascular prevention, *Raffaele De Caterina, Paul M Ridker, and Erica Michelotti*

16: Antithrombotic strategies in patients undergoing elective percutaneous coronary interventions and in chronic coronary syndromes without interventions, *Antonio Greco and Davide Capodanno*

17: Antithrombotic therapy in ST-elevation acute myocardial infarction and non-ST elevation acute coronary syndromes, *William A. E. Parker, Raffaele De Caterina, David J. Moliterno, Steen Dalby Kristensen and Robert F. Storey*

18: Anti-thrombotic therapy for patients with prosthetic valves and during structural percutaneous interventions, *Naoki Misumida, Mohamad Alkhouli, and David J. Moliterno*

19: Antithrombotic therapies in ischaemic stroke, *Hans Christoph Diener, Graeme J. Hankey, and John W. Eikelboom*

20: Antithrombotic therapy in patients with patent foramen ovale (PFO), PFO closure, left ventricular mural thrombus, atrial thrombus, and catheter-related thrombosis, *Jens Erik Nielsen-Kudsk, Kasper Korsholm, Asger Andersen, and Erik Lerkevang Grove*

21: Atrial fibrillation: current and forthcoming antithrombotic therapies, *Raffaele De Caterina and Rossella Marcucci*

22: Venous thromboembolism: prophylaxis and treatment, *Chaozer Er, Walter Ageno, and Ander Cohen*

23: Biomarker-based risk stratification in cardiovascular disease, *Lars C. Wallentin, Ziad Hijazi, Gorav Bartra, and Johan Lindbäck*

### **Section 4: Special situations**

24: Antithrombotic therapies in inherited or acquired thrombophilia, *Vittorio Pengo and Gentian Denas*

25: Prevention and treatment of bleeding related to antithrombotic drug treatment, *Roxana Mehran, Alessandro Spirito, George Dangas, and David Cao*

26: Management of patients treated with antithrombotic drugs undergoing surgery, *Michael Maeng, Steen Dalby Kristensen, and Jolanta M. Siller-Matula*

27:Antithrombotic therapy in patients with atrial fibrillation and recent coronary stenting, with or without an acute coronary syndrome, *Alexander C Fanaroff, Renato D Lopes, John H Alexander*

28:Prevention and treatment of venous and arterial thrombosis in patients with specific conditions: diabetes, renal insufficiency, thrombophilia and pregnancy, *Stefan Agewall, Vanessa Roldán, and Francisco Marín*

29:Antithrombotic agents and drug-drug interactions, *Steven P. Dunn, Craig J. Beavers, and David J. Moliterno*

30:Personalised antithrombotic therapy: Measuring individual variation and monitoring, *Jur ten Berg, Dirk Sibbning, Wout W.A. van den Broek, and Konstantinos D. Rizas*

31:Drug development, clinical trials, and regulatory requirements, *Serge Korjian, Yazan Daaboul, and C. Michael Gibson*